奥利司他对患有暴饮暴食症的肥胖患者的影响。
Effect of orlistat in obese patients with binge eating disorder.
作者信息
Golay Alain, Laurent-Jaccard Anne, Habicht Frank, Gachoud Jean-Pierre, Chabloz Mireille, Kammer Anne, Schutz Yves
机构信息
Service of Therapeutic Education for Chronic Diseases, University Hospital Geneva, CH-1211 Geneva 14, Switzerland.
出版信息
Obes Res. 2005 Oct;13(10):1701-8. doi: 10.1038/oby.2005.208.
OBJECTIVE
Binge eating disorder represents a significant public health problem, with up to 50% of weight loss program participants displaying this disorder. In previous studies with orlistat, patients with binge eating disorder were excluded. The goal of this study was to assess the efficacy of orlistat in obese patients with binge eating disorder.
RESEARCH METHODS AND PROCEDURES
Eighty-nine patients with clinically diagnosed binge eating disorder and a BMI > or = 30 kg/m2 were randomized in double-blind fashion to 24 weeks of treatment with 120 mg of orlistat or placebo three times daily, in combination with a mildly reduced-calorie diet.
RESULTS
After 24 weeks, the mean weight loss from baseline for orlistat-treated patients was significantly greater than for patients receiving placebo (-7.4% vs. -2.3%; p = 0.0001) (intent-to-treat analysis). The overall Eating Disorder Inventory 2 score at week 24 was significantly lower in patients treated with orlistat than in those in the placebo group (p = 0.011).
DISCUSSION
Orlistat may be considered as part of the management for patients with obesity and binge eating disorder.
目的
暴饮暴食症是一个重大的公共卫生问题，高达50%的减肥项目参与者患有这种疾病。在之前使用奥利司他的研究中，患有暴饮暴食症的患者被排除在外。本研究的目的是评估奥利司他对患有暴饮暴食症的肥胖患者的疗效。
研究方法和步骤
89名临床诊断为暴饮暴食症且BMI≥30kg/m²的患者以双盲方式随机分组，接受为期24周的治疗，其中一组每日三次服用120mg奥利司他，另一组服用安慰剂，同时搭配轻度低热量饮食。
结果
24周后，接受奥利司他治疗的患者自基线起的平均体重减轻幅度显著大于接受安慰剂的患者（-7.4%对-2.3%；p = 0.0001）（意向性分析）。在第24周时，接受奥利司他治疗的患者的总体饮食失调量表2得分显著低于安慰剂组患者（p = 0.011）。
讨论
奥利司他可被视为肥胖和暴饮暴食症患者治疗方案的一部分。
Zotero 插件